

Subject index

Volume 61 (2004)

- 2–5A antisense**; RNase L; RSV; Ribavirin; Combination therapy **61**, 195
- 6-Azauridine**; Chikungunya virus; Semliki Forest virus; Alphavirus; Interferon; Ribavirin **61**, 111
- Acyclovir**; Herpes simplex virus; Resistance mutation; Polymorphism; Thymidine kinase; DNA polymerase **61**, 83
- Acyclovir**; Varicella-zoster virus; Drug-resistant mutants; Penciclovir **61**, 181
- Adefovir**; Hepatitis B virus; Clinical isolate; Drug susceptibility; Drug resistance **61**, 27
- Adenoviral conjunctivitis**; Adenovirus; Cidofovir; Cotton rat **61**, 63
- Adenovirus**; Adenoviral conjunctivitis; Cidofovir; Cotton rat **61**, 63
- AIDS**; Antiretroviral drugs; Chemotherapy; Cancer; HIV **61**, 1
- Allium sativum**; Diallyl trisulfide; Murine cytomegalovirus; Hepatitis; Treatment **61**, 125
- Alphavirus**; Chikungunya virus; Semliki Forest virus; Interferon; Ribavirin; 6-Azauridine **61**, 111
- Anti-rhinovirus drug**; 2-Furylmercury chloride; Viral RNA synthesis inhibitor **61**, 189
- Anti-viral agents**; Rhinovirus; siRNA; RNA silencing **61**, 49
- Antibody**; HIV; Phage display; gp120; Inhibitors; Vaccines **61**, 161
- Antibody**; Porphyrin; HIV; gp120; Polyanion; Photosensitizer **61**, 37
- Antiretroviral drugs**; Chemotherapy; Cancer; HIV; AIDS **61**, 1
- Antiretroviral resistance**; Glycyl-prolyl-glycine-amide; Tripeptides **61**, 119
- Antiretrovirals**; Chemokine mRNA levels; Mononucleated cells; NNRTIs; PIs; HIV **61**, 207
- Antiviral activity**; Lactoferricin; Herpes simplex virus; Heparan sulfate; Structure–activity relation **61**, 101
- Antiviral drugs**; Herpes simplex virus; Treatment **61**, 73
- Antiviral**; Hops; Xanthohumol; *iso*-Xanthohumol; *iso*- α -Acid; Lead compounds **61**, 57
- Antivirus**; Shrimp; *Penaeus monodon*; Hemocyanin **61**, 93
- 3C protease**; Human rhinovirus; Serotypes; Inhibitor **61**, 153
- Cancer**; Antiretroviral drugs; Chemotherapy; HIV; AIDS **61**, 1
- CD4-lymphocytes**; Protease inhibitors; Therapy; Reservoirs; HAART **61**, 133
- Chemokine mRNA levels**; Mononucleated cells; Antiretrovirals; NNRTIs; PIs; HIV **61**, 207
- Chemotherapy**; Antiretroviral drugs; Cancer; HIV; AIDS **61**, 1
- Chikungunya virus**; Semliki Forest virus; Alphavirus; Interferon; Ribavirin; 6-Azauridine **61**, 111
- Cidofovir**; Adenovirus; Adenoviral conjunctivitis; Cotton rat **61**, 63
- Clinical isolate**; Hepatitis B virus; Drug susceptibility; Drug resistance; Adefovir **61**, 27
- Combination therapy**; RNase L; 2–5A antisense; RSV; Ribavirin **61**, 195
- Cotton rat**; Adenovirus; Adenoviral conjunctivitis; Cidofovir **61**, 63
- CTP synthetase**; 3TC; HIV; PBMC **61**, 67
- Diallyl trisulfide**; *Allium sativum*; Murine cytomegalovirus; Hepatitis; Treatment **61**, 125
- DNA polymerase**; Herpes simplex virus; Acyclovir; Resistance mutation; Polymorphism; Thymidine kinase **61**, 83
- Drug resistance**; Hepatitis B virus; Clinical isolate; Drug susceptibility; Adefovir **61**, 27
- Drug susceptibility**; Hepatitis B virus; Clinical isolate; Drug resistance; Adefovir **61**, 27
- Drug-resistant mutants**; Varicella-zoster virus; Acyclovir; Penciclovir **61**, 181
- 2-Furylmercury chloride**; Anti-rhinovirus drug; Viral RNA synthesis inhibitor **61**, 189
- Glycyl-prolyl-glycine-amide**; Tripeptides; Antiretroviral resistance **61**, 119
- gp120**; HIV; Antibody; Phage display; Inhibitors; Vaccines **61**, 161

- gp120**; Porphyrin; HIV; Polyanion; Photosensitizer; Antibody **61**, 37
- HAART**; HIV; Resistance; Virological failure **61**, 129
- HAART**; Protease inhibitors; Therapy; Reservoirs; CD4-lymphocytes **61**, 133
- Hemocyanin**; Shrimp; *Penaeus monodon*; Antivirus **61**, 93
- Heparan sulfate**; Lactoferricin; Antiviral activity; Herpes simplex virus; Structure–activity relation **61**, 101
- Hepatitis B virus**; Clinical isolate; Drug susceptibility; Drug resistance; Adefovir **61**, 27
- Hepatitis**; *Allium sativum*; Diallyl trisulfide; Murine cytomegalovirus; Treatment **61**, 125
- Herpes simplex virus**; Acyclovir; Resistance mutation; Polymorphism; Thymidine kinase; DNA polymerase **61**, 83
- Herpes simplex virus**; Lactoferricin; Antiviral activity; Heparan sulfate; Structure–activity relation **61**, 101
- Herpes simplex virus**; Treatment; Antiviral drugs **61**, 73
- HIV**; 3TC; CTP synthetase; PBMC **61**, 67
- HIV**; Antibody; Phage display; gp120; Inhibitors; Vaccines **61**, 161
- HIV**; Antiretroviral drugs; Chemotherapy; Cancer; AIDS **61**, 1
- HIV**; Chemokine mRNA levels; Mononucleated cells; Antiretrovirals; NNRTIs; PIs **61**, 207
- HIV**; HAART; Resistance; Virological failure **61**, 129
- HIV**; Porphyrin; gp120; Polyanion; Photosensitizer; Antibody **61**, 37
- HIV**; Methylene blue; Photoinactivation; RNA viruses; West Nile Virus **61**, 141
- HIV**; Resistance; Protease inhibitors; Mutations; Library **61**, 173
- Hops**; Xanthohumol; *iso*-Xanthohumol; *iso*- α -Acid; Lead compounds; Antiviral **61**, 57
- HSV**; Resveratrol; In vivo **61**, 19
- Human rhinovirus**; 3C protease; Serotypes; Inhibitor **61**, 153
- In vivo**; HSV; Resveratrol **61**, 19
- Inhibitor**; Human rhinovirus; 3C protease; Serotypes **61**, 153
- Inhibitors**; HIV; Antibody; Phage display; gp120; Vaccines **61**, 161
- Interferon**; Chikungunya virus; Semliki Forest virus; Alphavirus; Ribavirin; 6-Azauridine **61**, 111
- iso*- α -Acid; Hops; Xanthohumol; *iso*-Xanthohumol; Lead compounds; Antiviral **61**, 57
- iso*-Xanthohumol; Hops; Xanthohumol; *iso*- α -Acid; Lead compounds; Antiviral **61**, 57
- Lactoferricin**; Antiviral activity; Herpes simplex virus; Heparan sulfate; Structure–activity relation **61**, 101
- Lead compounds**; Hops; Xanthohumol; *iso*-Xanthohumol; *iso*- α -Acid; Antiviral **61**, 57
- Library**; HIV; Resistance; Protease inhibitors; Mutations **61**, 173
- Methylene blue**; Photoinactivation; RNA viruses; West Nile Virus; HIV **61**, 141
- Mononucleated cells**; Chemokine mRNA levels; Antiretrovirals; NNRTIs; PIs; HIV **61**, 207
- Murine cytomegalovirus**; *Allium sativum*; Diallyl trisulfide; Hepatitis; Treatment **61**, 125
- Mutants**; Syncytial virus; Phenotypic resistance **61**, 165
- Mutations**; HIV; Resistance; Protease inhibitors; Library **61**, 173
- NNRTIs**; Chemokine mRNA levels; Mononucleated cells; Antiretrovirals; PIs; HIV **61**, 207
- PBMC**; 3TC; CTP synthetase; HIV **61**, 67
- Penaeus monodon*; Shrimp; Hemocyanin; Antivirus **61**, 93
- Penciclovir**; Varicella-zoster virus; Drug-resistant mutants; Acyclovir **61**, 181
- Phage display**; HIV; Antibody; gp120; Inhibitors; Vaccines **61**, 161
- Phenotypic resistance**; Mutants; Syncytial virus; West Nile Virus; HIV **61**, 165
- Photoinactivation**; Methylene blue; RNA viruses; West Nile Virus; HIV **61**, 141
- Photosensitizer**; Porphyrin; HIV; gp120; Polyanion; Antibody **61**, 37
- PIs**; Chemokine mRNA levels; Mononucleated cells; Antiretrovirals; NNRTIs; HIV **61**, 207
- Polyanion**; Porphyrin; HIV; gp120; Photosensitizer; Antibody **61**, 37
- Polymorphism**; Herpes simplex virus; Acyclovir; Resistance mutation; Thymidine kinase; DNA polymerase **61**, 83
- Porphyrin**; HIV; gp120; Polyanion; Photosensitizer; Antibody **61**, 37
- Protease inhibitors**; HIV; Resistance; Mutations; Library **61**, 173
- Protease inhibitors**; Therapy; Reservoirs; HAART; CD4-lymphocytes **61**, 133
- Reservoirs**; Protease inhibitors; Therapy; HAART; CD4-lymphocytes **61**, 133
- Resistance mutation**; Herpes simplex virus; Acyclovir; Polymorphism; Thymidine kinase; DNA polymerase **61**, 83
- Resistance**; HIV; HAART; Virological failure **61**, 129
- Resistance**; HIV; Protease inhibitors; Mutations; Library **61**, 173
- Resveratrol**; HSV; In vivo **61**, 19

Rhinovirus; siRNA; RNA silencing; Anti-viral agents **61**, 49

Ribavirin; Chikungunya virus; Semliki Forest virus; Alphavirus; Interferon; 6-Azaauridine **61**, 111

Ribavirin; RNase L; 2–5A antisense; RSV; Combination therapy **61**, 195

RNA silencing; Rhinovirus; siRNA; Anti-viral agents **61**, 49

RNA viruses; Methylene blue; Photoinactivation; West Nile Virus; HIV **61**, 141

RNase L; 2–5A antisense; RSV; Ribavirin; Combination therapy **61**, 195

RSV; RNase L; 2–5A antisense; Ribavirin; Combination therapy **61**, 195

Semliki Forest virus; Chikungunya virus; Alphavirus; Interferon; Ribavirin; 6-Azaauridine **61**, 111

Serotypes; Human rhinovirus; 3C protease; Inhibitor **61**, 153

Shrimp; *Penaeus monodon*; Hemocyanin; Antivirus **61**, 93

siRNA; Rhinovirus; RNA silencing; Anti-viral agents **61**, 49

Structure–activity relation; Lactoferricin; Antiviral activity; Herpes simplex virus; Heparan sulfate **61**, 101

Syncytial virus; Mutants; Phenotypic resistance **61**, 165

3TC; CTP synthetase; HIV; PBMC **61**, 67

Therapy; Protease inhibitors; Reservoirs; HAART; CD4-lymphocytes **61**, 133

Thymidine kinase; Herpes simplex virus; Acyclovir; Resistance mutation; Polymorphism; DNA polymerase **61**, 83

Treatment; *Allium sativum*; Diallyl trisulfide; Murine cytomegalovirus; Hepatitis **61**, 125

Treatment; Herpes simplex virus; Antiviral drugs **61**, 73

Tripeptides; Glycyl-prolyl-glycine-amide; Antiretroviral resistance **61**, 119

Vaccines; HIV; Antibody; Phage display; gp120; Inhibitors **61**, 161

Varicella-zoster virus; Drug-resistant mutants; Acyclovir; Penciclovir **61**, 181

Viral RNA synthesis inhibitor; Anti-rhinovirus drug; 2-Furylmercury chloride **61**, 189

Virological failure; HIV; HAART; Resistance **61**, 129

West Nile virus; Methylene blue; Photoinactivation; RNA viruses; HIV **61**, 141

Xanthohumol; Hops; *iso*-Xanthohumol; *iso*- α -Acid; Lead compounds; Antiviral **61**, 57